Mutations in the CTNS gene encoding the lysosomal membrane cystine transporter cystinosin are the cause of cystinosis, an autosomal recessive lysosomal storage disease. More than 140 CTNS mutations have been reported worldwide. Recent studies have discovered that cystinosin exerts other key cellular functions beyond cystine transport such as regulation of oxidative state, lysosomal dynamics and autophagy. Here, we review the different mutations described in the CTNS gene and the geographical distribution of incidence. In addition, the characteristics of the various mutations in relation to the functions of cystinosin needs to be further elucidated. In this review, we highlight the functional consequences of the different mutations in correlation with the clinical phenotypes. Moreover, we propose how this understanding would be fundamental for the development of new technologies through targeted gene therapy, holding promises for a possible cure of the kidney and extra-renal phenotypes of cystinosis.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495270DOI Listing

Publication Analysis

Top Keywords

ctns gene
12
functional consequences
8
consequences mutations
8
mutations ctns
8
mutations
6
molecular basis
4
basis cystinosis
4
cystinosis geographic
4
geographic distribution
4
distribution functional
4

Similar Publications

While it has been appreciated for decades that lysosomes can import cysteine, its for organismal physiology is unclear. Recently, the MFSD12 transmembrane protein was shown to be necessary to import cysteine into lysosomes (and melanosomes), enabling the study of these processes using genetic tools. Here, we find that mice lacking die between embryonic days 10.

View Article and Find Full Text PDF

Background/objectives: Genetic newborn screening (NBS) has already entered the phase of common practice in many countries. In Germany, spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID) and sickle cell disease (SCD) are currently a mandatory part of NBS. Here, we describe the experience of six years of genetic NBS including the prevalence of those three diseases in Germany.

View Article and Find Full Text PDF
Article Synopsis
  • Cysteamine is the only treatment for cystinosis, a genetic disorder affecting kidneys, eyes, and muscles, but only manages symptoms and has side effects.
  • There is a need for new therapies, which involves understanding how cysteamine works at the molecular level, particularly its impact on proteins in cystinotic skin fibroblasts.
  • Research shows that cysteamine influences specific lysosomal proteins and partially reverses protein differences in cystinotic cells, providing insights into its therapeutic benefits and limitations.
View Article and Find Full Text PDF
Article Synopsis
  • Imerslund-Gräsbeck syndrome (IGS) is a rare genetic condition that leads to anemia and the body not absorbing vitamin B12 properly.
  • A 23-month-old baby in Italy was diagnosed with IGS after showing serious health issues, but vitamin B12 treatment helped improve the situation.
  • Genetic tests revealed two unusual changes in a specific gene, which are linked to the condition, and it's important to diagnose IGS early to avoid serious problems.
View Article and Find Full Text PDF

Ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) are important agents for treating multidrug-resistant infections. In this study, we evaluated the molecular characteristics of 300 globally collected clinical isolates non-susceptible (NS) to CZA, C/T, or both agents. Isolates were CZA-NS and C/T-NS ( = 57), CZA-susceptible (S) and C/T-NS ( = 145), or CZA-NS and C/T-S ( = 98) selected from the Antimicrobial Testing Leadership and Surveillance (ATLAS) surveillance program from 2020 to 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!